FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Eris Lifesciences FCF Yield % Related Terms
Eris Lifesciences FCF Yield % Historical Data
* Premium members only.
The historical data trend for Eris Lifesciences's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eris Lifesciences FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Eris Lifesciences's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eris Lifesciences (NSE:ERIS) has a FCF Yield % of 1.20 as of Jul. 03, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Eris Lifesciences and its competitors. According to the industry distribution chart, Eris Lifesciences ranks #457 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 45.4%.
Is Eris Lifesciences' FCF Yield % too high?
Eris Lifesciences' current FCF Yield % is 1.20. The Drug Manufacturers industry median FCF Yield % is 0.67. Eris Lifesciences' value of 1.20 is 80.5% above this industry median. Based on the distribution chart, Eris Lifesciences ranks #457 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Eris Lifesciences has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' FCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Eris Lifesciences ranks #457 out of 1006 companies for FCF Yield %. This puts Eris Lifesciences in the upper half of its industry. The industry median FCF Yield % is 0.67. Eris Lifesciences' value of 1.20 is 80.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eris Lifesciences's current FCF Yield % of 1.20 is 80.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Eris Lifesciences and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eris Lifesciences's current FCF Yield % is 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (NSE:ERIS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,645.71, compared to a current price of ₹1,448.70 — trading 12% below its estimated fair value. The current FCF Yield % is 1.20 and 80.5% above the Drug Manufacturers industry median of 0.67. Eris Lifesciences' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Eris Lifesciences (NSE:ERIS), the current FCF Yield % is 1.20 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eris Lifesciences (NSE:ERIS) Overvalued in 2026?
Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued.
The current stock price of ₹1,448.70 is trading 12% below its estimated GF Value™ of ₹1,645.71.
GuruFocus considers Eris Lifesciences to be Modestly Undervalued.
Key valuation signals for NSE:ERIS:
FCF Yield %: 1.20
GF Value™: ₹1,645.71 vs. price of ₹1,448.70 (12% below fair value)
Industry Position: 80.5% above the Drug Manufacturers median (#457 of 1006)
No single metric tells the full story. See the NSE:ERIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
91GF Score
Get the complete analysis for NSE:ERIS
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ERIS has been successfully added to your 
